查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1884041

白喉、破傷風和百日咳 (DTP) 疫苗市場規模、佔有率、成長及全球產業分析：按類型、應用和地區劃分的洞察與預測 (2024-2032)

Diphtheria, Tetanus, and Pertussis (DTP) Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 161 Pages | 商品交期: 請詢問到貨日

價格

白喉、破傷風和百日咳 (DTP) 疫苗市場成長驅動因子

由於傳染病病例的增加、疫苗接種計劃的加強以及疫苗技術的進步，全球白喉、破傷風和百日咳 (DTP) 疫苗市場持續穩步增長。報告顯示，該市場預計將在 2024 年達到 102.3 億美元，到 2025 年將增長至 116.9 億美元，並在 2032 年迅速達到 333.8 億美元。這反映了隨著各國政府和國際衛生組織提高疫苗接種覆蓋率，該市場強勁的成長動能。 DTP疫苗對於預防危及生命的細菌感染至關重要，其在兒童和成人免疫接種計畫中的市場需求持續成長。

市場概覽

DTP疫苗可預防嬰幼兒常見的三種嚴重細菌感染：白喉、破傷風和百日咳。多種配方，包括DTaP、Tdap、DT/Td和聯合疫苗，可涵蓋廣泛的年齡層。疾病發生率的上升是推動疫苗普及的關鍵因素。世界衛生組織（世衛組織）報告稱，2022年全球百日咳病例將超過62,500例，其中僅西太平洋地區就有39,000例，凸顯了百日咳的持續威脅。如此高的感染率有力地證明了進行常規兒童免疫接種和加強免疫接種計劃的必要性。

此外，葛蘭素史克（GSK plc）、賽諾菲（Sanofi）、默克（Merck & Co.）、印度血清研究所（Serum Institute of India）、Biological E Limited 和 BioNet Asia 等主要製藥公司正透過持續供應、創新和全球分銷能力來鞏固市場地位。

市場成長驅動因素

疫苗可預防疾病負擔沉重

呼吸道細菌感染發生率的上升是推動市場成長的最重要因素之一。根據美國疾病管制與預防中心（CDC）發布的 2024 年中期報告，2024 年將確診 35,435 例百日咳病例，其中超過 6,500 例為 1 至 6 歲兒童。這凸顯了主動接種疫苗的迫切性，尤其是在兒童群體中。

擴大免疫接種計畫

世界各國政府正在進行宣傳活動，以確保及時接種疫苗。例如，2025年4月，中國在全國兒童免疫日之際，開展了一項全國性的宣傳活動，向家庭普及百日咳的風險和接種疫苗的好處。

同樣，全球疫苗免疫聯盟（GAVI）在2023年更新的疫苗接種計劃中，在符合條件的國家引入了百白破加強劑和六價疫苗，從而擴大了疫苗接種覆蓋範圍。

市場限制

疫苗猶豫與認知不足

在低收入地區，宗教誤解、安全疑慮和教育不足阻礙了疫苗的廣泛接種。在吉爾吉斯斯坦，截至2024年底，仍有超過22,000名兒童因拒絕接種疫苗或受到錯誤訊息誤導而未接種疫苗，這表明疫苗接種工作仍面臨持續挑戰。

冷鏈限制

對溫度敏感的百白破疫苗需要持續儲存在2°C至8°C的溫度下。根據印度國家疫苗浪費評估報告，13.5%的百白破疫苗因冷鏈故障而被浪費，直接影響了疫苗供應的可靠性。

市場機會

政府支持並擴大資金投入

各國政府正大力投資全國疫苗接種運動。例如，印度2025年針對學齡兒童的破傷風白喉疫苗接種運動提高了加強劑的接種覆蓋率。同樣，巴西和圭亞那將於2025年舉辦“跨國免疫週”，為弱勢群體接種疫苗。

轉換成重組技術

現代基因工程方法正在提高免疫原性和保護持續時間。 BioNet Asia 的重組百日咳疫苗已於 2024 年提交給歐洲藥品管理局 (EMA)，這標誌著疫苗研發正朝著更安全、更有效的方向發展，並為新的市場成長鋪平道路。

細分市場概覽

依技術分類

  • 由於滅活疫苗的廣泛應用以及世界衛生組織報告的 2023 年嬰兒 DTP-3 疫苗接種率達到 84%，因此滅活疫苗將在 2024 年佔主導地位。
  • 隨著各公司開發出更安全、免疫原性更強的配方，預計從 2025 年到 2032 年，重組技術將變得更加普及。

按類型

  • 由於DTaP疫苗在嬰幼兒免疫接種中的作用，其在2024年佔市場主導地位。
  • Tdap疫苗在較大兒童、成人和孕婦中的使用量持續穩定成長。

依年齡組

  • 由於感染率高和強制性疫苗接種計劃，兒科在2024年佔市場主導地位。
  • 由於每10年進行一次加強免疫接種，成人需求保持穩定。

按分銷管道

  • 由於國家免疫計劃，政府供應鏈佔最大佔有率。
  • 隨著疫苗接種管道的擴大，醫院和零售藥局的市佔率也在成長。

區域概覽

北美

預計2024年，北美市場規模將達到58.6億美元，憑藉高疾病通報率、先進的醫療保健系統和強大的供應鏈，引領全球市場。預計到2024年，美國百日咳病例數將激增至11,568例，將推動疫苗需求。

亞太地區

預計到2032年，經濟高效的疫苗、龐大的人口規模以及政府主導的疫苗接種運動將推動亞太地區市場以最高的複合年增長率成長。

歐洲

得益於獲得世衛組織認證的監管設施（例如，德國將於2024年被指定為世衛組織白喉合作中心），保持著較高的市場佔有率。

拉丁美洲、中東和非洲

透過跨國努力和農村疫苗接種活動，疫苗接種率正在緩慢但穩定地提高。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 各國主要疾病流行情形（2024 年）
  • 主要產業趨勢（新產品發表、併購、合作等）
  • 主要公司產品線分析
  • 各國白喉-破傷風-百日咳 (DTP) 疫苗接種率概述

章節5：全球白喉-破傷風-百日咳 (DTP) 疫苗市場分析、洞察與預測 (2019-2032)

  • 市場分析、洞察與預測 - 按技術分類
    • 滅活​​疫苗
    • 其他
  • 市場分析、洞察與預測 - 按類型分類
    • DTaP 疫苗
    • Tdap 疫苗
    • DT/Td 疫苗
    • 其他
  • 市場分析、洞察與預測 - 按年齡組分類
    • 兒童疫苗
    • 成人疫苗
  • 市場分析、洞察與預測 - 按分銷管道分類
    • 醫院和零售藥局
    • 政府供應商
    • 其他
  • 市場分析、洞察與預測 - 按地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美白喉-破傷風-百日咳 (DTP) 疫苗市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲白喉、破傷風和百日咳 (DTP) 疫苗市場分析、洞察與預測 (2019-2032)

  • 依國家/地區
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞半島
    • 歐洲其他地區

第八章：亞太地區白喉、破傷風和百日咳 (DTP) 疫苗市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲白喉、破傷風和百日咳 (DTP) 疫苗市場分析、洞察和預測 (2019-2032)

  • 依國家/地區
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第十章：中東和非洲白喉-破傷風-百日咳 (DTP) 疫苗市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 海灣合作委員會 (GCC)
    • 南非
    • 其他中東和非洲國家

第十一章：競爭分析

  • 全球市佔率分析 (2024)
  • 公司簡介
  • 葛蘭素史克 (GSK plc)
  • 賽諾菲 (Sanofi)
  • 默克公司 (Merck & Co., Inc.)
  • 寶靈生物製藥株式會社 (Boryung Biopharma Co.)
  • 印度血清研究所 (Serum Institute of India Pvt.)有限公司
  • 武漢生物製品研究所有限公司
  • BioNet-Asia
  • Bio Farma
  • Biological E Limited
Product Code: FBI113648

Growth Factors of diphtheria, tetanus, and pertussis (DTP) vaccines Market

The global diphtheria, tetanus, and pertussis (DTP) vaccines market is experiencing robust expansion driven by rising infectious disease cases, strengthened immunization programs, and advancements in vaccine technologies. According to the report, the market reached USD 10.23 billion in 2024, is expected to grow to USD 11.69 billion by 2025, and is projected to surge to USD 33.38 billion by 2032, reflecting a strong trajectory as governments and global health organizations increase vaccination coverage. With DTP vaccines essential for preventing life-threatening bacterial infections, the market continues to gain momentum across pediatric and adult immunization programs.

Market Overview

DTP vaccines protect against three severe bacterial infections-diphtheria, tetanus, and pertussis-commonly affecting infants and young children. Multiple formulations such as DTaP, Tdap, DT/Td, and combination vaccines ensure broad applicability across age groups. Rising disease incidence is a critical factor driving adoption. The WHO reported over 62,500 global pertussis cases in 2022, with 39,000 in the Western Pacific region alone, highlighting the continued threat of whooping cough. These high infection rates reinforce the need for routine childhood immunization and booster programs.

Furthermore, leading pharmaceutical companies such as GSK plc, Sanofi, Merck & Co., Serum Institute of India, Biological E Limited, and BioNet-Asia strengthen the market with continuous supply, innovation, and global distribution capabilities.

Market Growth Drivers

High Burden of Vaccine-Preventable Diseases

Growing cases of respiratory bacterial infections are one of the most significant market drivers. CDC's Provisional 2024 Report revealed 35,435 pertussis cases in 2024, with over 6,500 cases in children aged 1-6 years. This has increased the urgency for active immunization, particularly among pediatric populations.

Expanding Vaccination Programs

Governments worldwide are initiating awareness campaigns to ensure timely vaccinations. For example, in April 2025, China launched a nationwide campaign during National Children's Vaccination Day to educate families on pertussis risks and the benefits of immunization.

Similarly, GAVI's 2023 update introduced DTP booster doses and hexavalent vaccines in eligible countries, enabling broader coverage.

Market Restraints

Vaccine Hesitancy & Lack of Awareness

In low-income regions, religious misconceptions, safety concerns, and limited education restrict vaccination uptake. In the Kyrgyz Republic, more than 22,000 children remained unvaccinated by end-2024 due to refusals and misinformation, demonstrating persistent challenges.

Cold Chain Limitations

Temperature-sensitive DTP vaccines require continuous storage between 2°C-8°C. According to India's National Vaccine Wastage Assessment, 13.5% of DPT vaccines were wasted due to cold-chain failures, directly affecting supply reliability.

Market Opportunities

Growing Government Support & Funding

Governments are investing heavily in nationwide vaccination drives. For instance, India's 2025 Td Vaccination Campaign for schoolchildren enhanced booster dose coverage. Similarly, Brazil and Guyana's Cross-Border Vaccination Week (2025) aims to immunize vulnerable populations.

Shift Toward Recombinant Technologies

Modern genetic engineering methods improve immunogenicity and duration of protection. BioNet-Asia's 2024 submission to EMA for its recombinant pertussis vaccine marks a shift toward safer, more effective vaccines, fueling new market growth avenues.

Segmentation Overview

By Technology

  • Inactivated vaccines dominated 2024, driven by widespread use and WHO-reported 84% infant DTP-3 coverage in 2023.
  • Recombinant technologies are expected to gain traction from 2025-2032 as companies develop safer, more immunogenic formulations.

By Type

  • DTaP vaccines led 2024 due to their role in infant immunization.
  • Tdap vaccines continue to expand moderately for older children, adults, and pregnant women.

By Age Group

  • Pediatrics dominated the market in 2024 due to high infection rates and mandatory immunization schedules.
  • Adults maintain steady demand through booster doses every 10 years.

By Distribution Channel

  • Government suppliers held the largest share due to national immunization programs.
  • Hospital and retail pharmacies are growing as access to vaccinations expands.

Regional Insights

North America

Generated USD 5.86 billion in 2024, leading globally due to high disease reporting, advanced health systems, and strong supply chains. U.S. pertussis cases surged to 11,568 in 2024, increasing vaccination demand.

Asia Pacific

Expected to grow at the highest CAGR through 2032, driven by cost-effective vaccines, large population, and government immunization drives.

Europe

Maintains strong share with WHO-recognized regulatory facilities, such as Germany's 2024 designation of a WHO Collaborating Center for Diphtheria.

Latin America & Middle East/Africa

Show moderate but rising adoption through cross-border and rural immunization initiatives.

Conclusion

With market value rising from USD 10.23 billion (2024) to USD 33.38 billion (2032), the global DTP vaccines market is poised for strong long-term expansion. Increasing disease prevalence, large-scale immunization campaigns, and advancements in recombinant technology will continue to strengthen global vaccine coverage and market growth.

Segmentation By Technology

  • Inactivated
  • Others

By Type

  • DTaP Vaccine
  • Tdap Vaccine
  • DT/ Td vaccines
  • Others

By Age Group

  • Pediatric
  • Adults

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Technology, Type, Age Group, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases, By Key Countries, 2024
  • 4.2. Key Industry Developments (Launches, Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Overview: Vaccination Coverage for Diphtheria Tetanus and Pertussis (DTP) Vaccines, By Key Countries

5. Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Technology
    • 5.1.1. Inactivated
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By Type
    • 5.2.1. DTaP Vaccine
    • 5.2.2. Tdap Vaccine
    • 5.2.3. DT/ Td vaccines
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adolts
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital & Retail Pharmacies
    • 5.4.2. Government Suppliers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Technology
    • 6.1.1. Inactivated
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By Type
    • 6.2.1. DTaP Vaccine
    • 6.2.2. Tdap Vaccine
    • 6.2.3. DT/ Td vaccines
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adolts
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital & Retail Pharmacies
    • 6.4.2. Government Suppliers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Technology
    • 7.1.1. Inactivated
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By Type
    • 7.2.1. DTaP Vaccine
    • 7.2.2. Tdap Vaccine
    • 7.2.3. DT/ Td vaccines
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adolts
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Government Suppliers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Technology
    • 8.1.1. Inactivated
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By Type
    • 8.2.1. DTaP Vaccine
    • 8.2.2. Tdap Vaccine
    • 8.2.3. DT/ Td vaccines
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adolts
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital & Retail Pharmacies
    • 8.4.2. Government Suppliers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Technology
    • 9.1.1. Inactivated
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By Type
    • 9.2.1. DTaP Vaccine
    • 9.2.2. Tdap Vaccine
    • 9.2.3. DT/ Td vaccines
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adolts
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital & Retail Pharmacies
    • 9.4.2. Government Suppliers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Technology
    • 10.1.1. Inactivated
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By Type
    • 10.2.1. DTaP Vaccine
    • 10.2.2. Tdap Vaccine
    • 10.2.3. DT/ Td vaccines
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adolts
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital & Retail Pharmacies
    • 10.4.2. Government Suppliers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sanofi
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Boryung Biopharma Co.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Serum Institute of India Pvt. Ltd.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Wuhan Institute of Biological Products Co., Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. BioNet-Asia.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Bio Farma
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Biological E Limited.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 2: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2033
  • Table 3: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2034
  • Table 4: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 5: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 6: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 7: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 8: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 9: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 10: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 11: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 12: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 13: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 14: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 15: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032
  • Table 16: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 17: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 18: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 19: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032
  • Table 21: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 22: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 23: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 24: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 25: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032
  • Table 26: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 27: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 28: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 29: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 30: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032

List of Figures

  • Figure 1: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2024 & 2032
  • Figure 3: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2024 & 2032
  • Figure 4: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group 2024 & 2032
  • Figure 5: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 6: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Region, 2024 & 2032
  • Figure 7: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2024 & 2032
  • Figure 8: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2024
  • Figure 9: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 10: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2024
  • Figure 11: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 12: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 13: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 14: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 15: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country, 2024 & 2032
  • Figure 16: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country, 2024
  • Figure 17: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2024 & 2032
  • Figure 18: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2024
  • Figure 19: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 20: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2024
  • Figure 21: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 22: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 23: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 24: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 25: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
  • Figure 26: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country/Sub-Region, 2024
  • Figure 27: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2024 & 2032
  • Figure 28: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2024
  • Figure 29: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 30: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2024
  • Figure 31: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 32: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 33: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 34: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 35: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
  • Figure 36: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country/Sub-Region, 2024
  • Figure 37: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2024 & 2032
  • Figure 38: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2024
  • Figure 39: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 40: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2024
  • Figure 41: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 42: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 43: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 44: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 45: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
  • Figure 46: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country/Sub-Region, 2024
  • Figure 47: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2024 & 2032
  • Figure 48: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2024
  • Figure 49: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 50: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2024
  • Figure 51: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 52: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 53: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 54: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 55: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
  • Figure 56: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country/Sub-Region, 2024
  • Figure 57: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Share (%), By Company, 2024